Follow-up appointments happen
The most recently approved type, tirzepatide [archived link], is called a dual agonist because it mimics the effects of two gut hormones, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide)
At Smiley Aesthetics, weve seen how weight gain isnt always about diet or willpower
This review will use the term MASLD, defined as the presence of hepatic steatosis with no other discernible cause, in conjunction with at least one cardiometabolic risk factor (CMRF), such as type 2 diabetes mellitus (T2DM), obesity, hypertension, or dyslipidemia
A large systemic review of cardiovascular outcomes of people taking GLP-1 agonists significantly reduces death from cardiovascular causes by 12% and stroke by 16%
"But there will come a day when we no longer see these access barriers for GLP-1s."